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Abstract
Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan®, Merck &
Co., Inc.) through the Mectizan Donation Programme. Recently, concern has been raised over the
appearance of suboptimal responses to ivermectin in Ghana – highlighting the potential threat of
the development of resistance to ivermectin. This report summarises a meeting held in Ghana to
set the research agenda for future onchocerciasis control. The aim of this workshop was to define
the research priorities for alternative drug and treatment regimes and control strategies to treat
populations with existing evidence of suboptimal responsiveness and define research priorities for
future control strategies in the event of the development of widespread ivermectin resistance.
Introduction
Since 1987 onchocerciasis control has relied on the dona-
tion of ivermectin (Mectizan®, Merck & Co., Inc.) through
the Mectizan Donation Programme (MDP). This pro-
gramme is rightly regarded as a model paradigm for mass
treatment control programmes [1]. The 20th anniversary
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programme has achieved [2]. As the African Programme
for Onchocerciasis Control (APOC) enters the phasing-
out period of the programme (2008–2015) a number of
ongoing and future challenges face the sustained delivery
of onchocerciasis control by national programmes. While
attention on the problems presented by 'fragile states',
poor primary health care systems and co-infection with
Loa loa are evident [2-4] – the role and priorities for
research activities to address complementary and alterna-
tive control strategies have received less attention. This is
particularly important in view of the conclusion that
onchocerciasis in Africa cannot be eliminated with exist-
ing tools [5]. To address this issue a meeting was held in
Ghana in April 2008. The aim of this meeting was to
review the current status of onchocerciasis control in
Ghana in light of evidence of poor-responsiveness to iver-
mectin, define the research priorities for alternative drug
and treatment regimes and control strategies to treat pop-
ulations with existing evidence of suboptimal responsive-
ness and define research priorities for future control
strategies in the event of the development of widespread
ivermectin resistance.
The current status of onchocerciasis control in Ghana
In Ghana, onchocerciasis is endemic in 9 out of 10
regions. About 3204 communities from 66 districts are
endemic in these regions. Some 247 of these communities
in Brong Ahafo and Ashanti regions have been designated
as Special Intervention Zones (SIZ), which are areas of
hyperendemicity, within the Pru River basin that serve as
the focus of Community-Directed Treatment with Iver-
mectin (CDTI). The total at risk population for onchocer-
ciasis is about 3.2 million.
Ivermectin distribution in Ghana started with the use of
mobile teams in 1987, with CDTI introduced in 1998.
Since the devolution of onchocerciasis control from the
former-OCP (Onchocerciasis Control Programme) to
Ghana (under APOC), the national programme has been
monitoring recrudescence through entomological and
epidemiological surveillance activities. Ivermectin treat-
ment started in lymphatic filariasis and onchocerciasis co-
endemic areas in 2001 and has undergone a gradual up-
scaling to cover 61 endemic districts by 2005. From 2002
to 2007 3.4 million people were treated through CDTI
with coverage ranging from 48.4 to 79.1%. Since 2006
onchocerciasis control has been implemented in the con-
text of the Neglected Tropical Diseases Control Pro-
gramme (NTDCP). Implementation of NTDCP started in
April 2007 on a pilot basis in 5 regions of Ghana.
Results from the entomological and epidemiological sur-
veillance activities have indicated fly infectivity levels and
infection in humans that require improved programme
attention. Results of surveys done in 2005, indicated high
infectivity rates of 1.82 per 1000 parous flies, from the
Asubende site within the Pru River basin. In 2006 results
again showed high infectivity rates of 0.556 – 1.01 per
1000 parous flies from sites within the White Volta, Kul-
pawn, Anum and Pra River basins. Fly nuisance was signif-
icantly high in each of the surveyed sites.
In 2004 epidemiological surveys showed a microfilaria
positive prevalence of 8.9% with 13 out of the 18 villages
surveyed having prevalence of more than 5%. About 2.8%
and 0.75% had visual impairment and total blindness
respectively. About 9 of the 24 communities surveyed in
2006 had prevalence rates above 5% with the highest
focus found in 3 sites in the Asante Akim district in
Ashanti region. Community microfilarial load (CMFL)
ranged from 0.56 – 2.89 mf per skin snip. A site within the
Pru River basin produced CMFL of 0.98, which is above
the threshold of 0.5 while results of other communities
were below this threshold.
A number of factors may contribute to the trends observed
from entomological and epidemiological surveys, includ-
ing CDTI coverage, individual compliance and the possi-
bility that the efficacy of ivermectin is compromised.
Evidence for poor responsiveness and resistance to 
ivermectin
Evidence for Sub-optimal Responses to Ivermectin
Suboptimal response (SOR) of Onchocerca volvulus to iver-
mectin is manifested by responses that are incompatible
with previous experience with multiple treatments. Criti-
cal to this definition is incontrovertible evidence of the
consumption by the subject of the number of treatments
under consideration. Additional factors are parasite expo-
sure to adequate concentrations of ivermectin and control
for the effects of ongoing transmission. SOR is usually sus-
pected when the prevalence of and/or the intensity of
infection by skin microfilariae are higher than expected
and is confirmed by direct examination of the adult
worms. Multiple treatments with ivermectin have marked
effects on embryogenesis [6]. Quantitative estimates have
ranged from an irreversible decline in microfilarial pro-
duction of ~30% per treatment [7], a reduction in the pro-
ductivity index of 83% [8] to arrest of development at the
single cell stage [9]. Thus when the factors listed above are
taken into account, the presence of normal reproductive
activity in female worms exposed to multiple treatments
is incompatible with a normal response.
An open case control hospital based study [10] enrolled
21 microfilaridermic and 7 amicrofilaridermic subjects
from two river basins in Ghana with little risk of ongoing
transmission and with documented consumption of ≥ 9
ivermectin treatments, and also 14 microfilaridermic iver-Page 2 of 7
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mission. Detailed clinical ophthalmological and
laboratory examinations were done. Ivermectin 150 μg/kg
was then administered. A pharmacokinetic component
determined drug exposure. Skin snipping and fly feeding
were done before and at days 8, 90 and 365. Embryo-
grams from adult female worms were examined at day 90.
The study determined that the significant microfilarider-
mias despite multiple treatments with ivermectin were
mainly attributable to the non-response of the adult
female worms and not to inadequate drug exposure or
other factors. This was confirmed in a 30-month follow
up study [11]. Microfilariae in general remained sensitive
to ivermectin.
In a two phase epidemiological study [12], 2501 individ-
uals were randomly selected from 19 onchocerciasis
endemic communities located in 3 river basins in Ghana.
Very stringent criteria were met by the communities and
detailed investigations provided incontrovertible evi-
dence of the consumption of 6–18 rounds of ivermectin
by the participants; one other community was ivermectin
naïve. The microfilaria prevalence and community micro-
filarial load ranged from 2.2% to 51.8%, and 0.06 micro-
filariae per snip to 2.85 microfilariae per snip,
respectively. Assessment of skin microfilariae 30 days after
150 μg/kg of ivermectin treatment showed 100% clear-
ance in more than 99% of subjects. However, re-snipping
of 342 initially skin snip positive participants from 10
communities at days 90 and 180 during the second phase
revealed an usually high repopulation rate at day 90 that
was confirmed at day 180 in 4 out of 10 communities.
This finding suggests that the adult female worms had not
responded to the known suppressive effects of the multi-
ple treatments of ivermectin administered previously.
The Ghana studies (either conducted with little risk of
new infections [10,11] or with ongoing transmission
[12]) yielded similar results and demonstrate that iver-
mectin remains a potent microfilaricide but that non-
responsive female adults may be present in some commu-
nities. This is also suggested by the much more rapid
return of skin microfilariae at 4–6 months in a subgroup
of subjects treated with a single dose of ivermectin and liv-
ing in a non-endemic area [13].
Genetic evidence of resistance to ivermectin
Drug resistance has been defined as a loss of the normal
response to treatment and is heritable [14]. Ivermectin
affects both the microfilariae, removing them from the
skin, and the adult worms, inhibiting their reproduction
for many weeks. Because of these various and prolonged
effects, and because ivermectin activity involves host
immunity, it is not reliable to assess efficacy in vitro. Phe-
notypic assessment of resistance needs to consider both
skin microfilarial loads (repopulation of the skin by
microfilariae), and worm fertility (by embryogram). A
meta-analysis was conducted of both these outcomes after
single-dose ivermectin following a systematic review of
early clinical and field trials and fitted a mathematical
model to the data [15]. Results were compared with those
obtained in a study of 10 repeatedly treated communities
in Ghana (with >10 annual treatments) [12]. This study
indicated continued high microfilaricidal activity of iver-
mectin but suggested that inhibition of reproduction by
adult worms was impaired in some repeatedly treated
communities in contrast to an ivermectin-naïve commu-
nity. Subsequent repopulation of skin by microfilariae
was faster than expected even after considering the inter-
study variability of the (also ivermectin-naïve) meta-anal-
ysis. A model for repopulation rates was fitted to micro-
filarial temporal profiles after treatment for each person
examined in one of the communities (treated for 10 years)
to quantify the level of inter-individual variability in par-
asitological response. Ivermectin resistance is common in
veterinary parasites and has a genetic basis associated with
selection on ATP-binding cassette (ABC) transporters (e.g.
P-glycoproteins) and β-tubulin. Onchocerca volvulus sam-
ples from communities in Ghana and Cameroon that
have received many treatments have been found to have
significant changes in similar genes (β-tubulin, P-glyco-
proteins and other ABC transporters) compared with
worms isolated from treatment-naïve subjects or the same
subjects prior to treatment [16,17]. These genetic changes
should be useful markers for ivermectin resistance moni-
toring. Genetic and parasitological data can be integrated
into mathematical models to assess the epidemiological
consequences of anthelmintic resistance, identify optimal
host characteristics and parasitic stages to sample, and
assist in the development of intervention strategies to
delay or manage resistance.
Alternative Chemotherapy, drug discovery and 
development
Antibiotic therapy
New and alternative treatments for filariasis are therefore
urgently needed. The break-through of using antibiotics to
target the bacterial symbiont of the parasite has identified
a novel treatment and target that offers a superior thera-
peutic alternative to current anthelminthic drugs [18-21].
The rationale for this novel treatment is the antibiotic tar-
geting of Wolbachia – a bacterial endosymbiont of filarial
parasites essential for worm development, fertility and
survival and inducer of inflammatory disease pathogene-
sis. A series of field trials against onchocerciasis and lym-
phatic filariasis have demonstrated that 4–8 week courses
of the antibiotic doxycycline deplete the bacteria and
result in the long-term sterility and most importantly
death of adult worms [18-21].Page 3 of 7
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with a regimen of daily treatment with 100 mg doxycy-
cline for 6 weeks, followed by ivermectin 4 months later,
which resulted in depletion of Wolbachia and female
worm sterility for 18 months in all worms except for a few
that were acquired after doxycycline treatment [21-23].
The data allowed the conclusion that this effect was due to
doxycycline alone [22]. In a more recent, placebo control-
led trial, treatment with a daily dose of 200 mg, either for
4 or 6 weeks (again followed by ivermectin), also lead to
sterility of female worms and more importantly to a mac-
rofilaricidal effect of 50 or 60%, respectively, observed at
21–27 months after treatment [24]. If one subtracted
those worms that had been newly acquired in the interval
after doxycycline treatment, the macrofilaricidal rate
would have been approximately 10% higher. The propor-
tion of dead female worms in ivermectin-only treated
patients who had received placebo instead of doxycycline
remained at levels equivalent to those found in onchocer-
comas from untreated patients (around 15%). The macro-
filaricidal effect of doxycycline appears to take >1 year to
manifest accounting for the lack of this activity in earlier
reports. In support of this, another study using 100 mg/
day of doxycycline for 5 weeks (without ivermectin) also
led to sterility and a 50% macrofilaricidal effect after 21–
27 months [25].
The 'slow-kill' outcome of doxycycline therapy has several
advantages including the elimination of the inflammatory
inducing bacteria [26,27] and avoidance of potential
adverse reactions to nematode products associated with a
rapid-kill as observed in loiasis co-infection [3].
The current major obstacles to the use of antibiotic ther-
apy in control of filariasis is the length of treatment,
which is considered to be logistically incompatible with
the community-directed treatment strategies used for
filariasis control and contraindication for children >9 and
pregnancy. Shorter regimes using combinations of exist-
ing antibiotics effective against Wolbachia require testing
to establish the minimum effective regime for integration
into existing control programmes to meet the program-
matic aims of eliminating filariasis or be used in more
restricted situations, such as during the 'mop-up' phase
and the end of programmes, in the event of the emergence
of resistance or poor responsiveness to existing drugs or in
individuals co-infected with Loa loa and at risk of severe
adverse reactions to ivermectin. Definition of the minimal
effective regime will also provide an important advance in
the treatment options for individual cases outside of con-
trolled areas.
In the case of communities co-infected with L. loa; the risk
of severe adverse events following ivermectin therapy in
individuals with high intensity of L. loa microfilaraemia
precludes the use of ivermectin in many of the forested
regions of APOC. The use of doxycycline in these commu-
nities has been determined in two trials in Cameroon. 1)
A placebo-controlled trial of doxycycline with or without
ivermectin in areas of low loaisis co-endemicity, and 2) a
trial of community-directed delivery of doxycycline alone
in communities with high prevalence of loaisis. The out-
come of these trials, which is currently under analysis,
should reveal the suitability of these approaches as an
alternative therapy for onchocerciasis in areas of loiasis
co-endemicity.
Anti-Wolbachia (A-WOL) Drug Discovery and 
Development
In an attempt to translate Anti-Wolbachia therapy into a
public health tool the A-WOL consortium has been estab-
lished through funding from the Bill and Melinda Gates
Foundation to find new drugs active against Wolbachia
that improve upon existing antibiotic therapy.
The principal goal is the establishment of anti-symbiotic
chemotherapy directed against Wolbachia compatible with
mass drug administration (MDA) programmes for human
filariasis. The expected health outcome would be an alter-
native treatment for human filariasis to ensure that the
long-term goals of global elimination of the public health
problems are achieved. A secondary goal is the establish-
ment of anti-symbiotic chemotherapy suitable for a more
restricted use, planned for an interim phase in which there is
yet no drug or drug combination available that is compatible
with MDA usage. For example, in the event of the emer-
gence of drug-resistance to existing treatment in limited
populations or as an alternative for communities co-
endemic for loiasis.
In order to achieve these goals A-WOL has identified four
major objectives to address the discovery and develop-
ment of new drugs and regimes against Wolbachia (see
Appendix 1). The strategy is intended to cover; 1) the opti-
mization of regimes of drugs with known activity against
Wolbachia (doxycycline and rifampicin, [28,29]) for inte-
gration into existing MDA programmes within 5 years, 2)
the evaluation of anti-Wolbachia drugs already licensed for
human use, which could enter control programme
deployment without the need for extended toxicity and
regulatory processes and 3) the identification of novel
drugs and compounds identified through high-through-
put screening and target discovery to provide a portfolio
of lead candidates in a product pipeline, which could be
used in future control and treatment approaches.
Progress during the first 12 months of the programme
includes the discovery of novel tetracyclines with
improved in vitro and in vivo efficacy to doxycycline, novel
classes of antibiotic and other drugs active against Wol-Page 4 of 7
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provide encouragement that the goals of the programme
will be achieved.
WHO-TDR: Anthelminthic Drug Discovery and 
Development
Drug discovery and development activities for onchocer-
ciasis continue under the TDR helminth drug initiative.
Drugs from a variety of sources are screened against
Onchocerca lienalis microfilariae and O. gutturosa adult
male worms in vitro and O. lienalis microfilariae in mice.
Hits from these screens are then tested against Brugia
pahangi in jirds and dogs. From 2006/7 some 5000 com-
pounds have been screened in vitro producing ~100 com-
pounds for follow-up and around 6 lead compounds for
optimization. In addition, cyclooctadepsipeptides such as
emodepside, show species-dependent activity against
filarial nematodes. Variability in sensitivity to larval and
adult stages is reported for Acanthocheilonema viteae, L. sig-
modontis and B. malayi [30], but it remains an effective
microfilaricide in all three species [31].
Another drug being developed for control programme use
is moxidectin (Wyeth). A partnership between endemic
countries, APOC, TDR and Wyeth is undertaking the
development required to determine whether moxidectin
has the efficacy and safety not only to eliminate onchocer-
ciasis as a public health problem but to eradicate
onchocerciasis. The development has progressed through
studies in healthy volunteers to an ongoing Phase II hos-
pital-based trial of up to 192 O. volvulus infected subjects
which will complete the 18 months efficacy follow up at
the end of 2009. Based on the safety and microfilaricidal
efficacy data obtained in this trial to date, initiation of a
large phase III trial is planned. This will be followed by a
study to determine a safe dose in children before applica-
tion for regulatory agency approval. Data from commu-
nity studies on safety, efficacy and effect on transmission
will be obtained before an expert meeting to assess
whether moxidectin can be recommended for use in con-
trol programmes by 2014.
Vector Control
Vector control was a major component of the onchocer-
ciasis control programme (OCP) and was based on rou-
tine aerial application of larvicides over a period of more
than 14 years. This is an expensive method of treating the
river, but was considered essential due to the vast area
within the project. Since OCP was completed, vector con-
trol has not been considered feasible or cost-effective in
the APOC countries, except for a few small isolated foci in
'special intervention zones' (SIZ).
In Ghana, vector control has virtually ceased, except for
limited activities associated with the Bui Dam construc-
tion, but in Cameroon, temephos has been applied across
the full width of the Sanaga river, at selected sites using
local boats. Three applications were made ideally at 7 day
intervals, with adult blackflies monitored on Perspex
sheets covered with a sticky substance, to determine when
a subsequent series of larvicide treatments should be
applied to keep adult fly populations below a threshold.
Other insecticides used in a rotation will be needed to
minimise the risk of resistance. Dosage applied was calcu-
lated according to WHO recommendations.
These control operations were required where areas of
tropical rain forest along the Nyong and Sanaga rivers
were de-populated due to the high incidence of onchocer-
ciasis and the constant irritation caused by the bites of the
vector Simulium spp. The latter affects people's skin and
prevents working a full day, so agricultural production has
declined. The severity of black flies is considered to have
increased and this may be partly due to hydroelectric
schemes along the Sanaga River.
So far larval control has been confined to major rapids on
the Sanaga, but to treat narrower rivers, larvicide could be
applied using motorised hydraulic knapsack sprayers fit-
ted with boomless nozzles to project the insecticide across
the river.
To minimise treatment of rivers, research is need to deter-
mine whether adult blackflies can be lured by an attract-
ant to insecticide treated screens as used in tsetse control,
and whether insecticide treated over-garments or bandana
at the wrists and ankles could reduce the impact of the
flies on field workers. Further research is needed to
improve monitoring and establish thresholds that deter-
mine when control is needed.
In Ghana on-going transmission shows that operational
research remains critical to sustain gains of the OCP and
improve onchocerciasis control. A closely monitored area-
wide blackfly management programme could signifi-
cantly reduce the populations of blackflies, and thus allow
agricultural productivity to increase in West Africa. By
integrating vector management with drug treatment, such
a programme could lead to better use of the drugs by those
affected by onchocerciasis. However, capacity building is
needed to increase local knowledge of vector ecology,
sampling procedures and control techniques.
Conclusion
The outcome of the meeting was a list of priorities for
research (Appendix 2). Some of these areas are ongoing
and funded, but a number of important areas require
additional support and renewed effort. Failure to grasp
the importance and urgency of addressing these activities
runs the serious risk of undoing much of the benefits andPage 5 of 7
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unanimous outcome was the belief that, where possible,
this research should be undertaken by African scientists
within endemic countries. Sufficient capacity building
and funding for such activities are urgently required if the
aims of the Yaoundé declaration [32] are to be realised
and the future control of onchocerciasis is to be secured.
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Appendix 1
A-WOL has four main objectives:
1) Regime Refinement – To address this we will carry out
two phase II field trials in Ghana on O. volvulus and W.
bancrofti to test combinations of doxycycline with
rifampicin at low doses to achieve shorter regimens to
define the optimal regime using drugs already licensed for
human use.
2) Assay development – To develop Wolbachia-cell line
assays compatible with combinational high throughput
screening (cHTS) technologies and as a novel tool to
screen existing and novel compounds for anti-symbiotic
activity.
3) Library Screening – To screen novel derivatives of tetra-
cycline (TC), large diversity libraries (~100 K compounds)
and combinations of existing drugs against Wolbachia.
4) Target Discovery – To identify targets and inhibitors of
key enzymatic and metabolic pathways predicted from
Wolbachia genomic annotation. To use bioinformatics to
identify the 'essential gene set' of Wolbachia and multi-
step computational approaches to identify potential drug
targets and develop a surrogate screening system in E. coli.
To use aptamer technology to identify inhibitors of novel
drug targets to incorporate into HTS.
Appendix 2
Research priorities
Mapping responsiveness to ivermectin
Information on the extent and geographical range of iver-
mectin responsiveness is needed through:
- Spatial and longitudinal monitoring of epidemiological,
parasitological, vector and clinical responses
- Investigation of parasite genetics in relation to drug sus-
ceptibility and the development of genetic markers to
quantify connectivity between parasite populations
Alternative/complementary/combined control strategies
- Improved integration of existing strategies of chemother-
apy and vector control
- Re-evaluation of control strategies for drugs with macro-
filaricidal or permanent sterilizing activity
- Continue development of macrofilaricidal drugs and
approaches to deplete the parasites of Wolbachia endo-
symbionts
Diagnostic tools
- To develop specific, rapid and less invasive tools to
improve mapping and provide prospective tools to define
control programme endpoint
Vector control
- Evaluate new methods of blackfly trapping for monitor-
ing and to reduce fly density
- Optimizing techniques to apply larviciding
- Develop research on blackfly attractants, reducing
human-vector contact, improved knowledge of vector-
parasite combinations
- Consider role of Community-directed activities for vec-
tor control
Quantitative population biology / Mathematical modelling
To assist in the planning of activities for:
- Identification and optimisation of indicator groups (in
the area of diagnostics and programme monitoring)
- Monitoring of resistance (detection and quantification
of genetic markers)
- Exploring different control scenarios, combinations of
control measures, timings of applications, etc. that can
also delay spread of drug resistance
- Vector biology, quantification of vector competence, vec-
tor population dynamics, insecticide resistance
Capacity building in all the areas above
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